Nonspecific immunity to SARS-CoV-2 by MTBVAC plus BCG tuberculosis vaccine

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Known Financial Commitments (USD)

    $343,440
  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Principle Investigator

    Pending
  • Research Location

    Spain, Europe
  • Lead Research Institution

    Universidad de Zaragoza.
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    Gender

  • Study Subject

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Nonspecific immunity to SARS-CoV-2 by MTBVAC plus BCG tuberculosis vaccine